Interferon-beta Therapy Reduces Cd4+ and Cd8+ T-cell Reactivity in Multiple Sclerosis.
From: Biochemisches Institut, Infektiologie, Justus-Liebig-Universität Giessen, Germany.
Immunology
- Publish Date: May 2007
- ISSN: 0019-2805
- Volume: 121
- Issue: 1
- Pages: 29-39
- Medium: Print
- Language: English
- Citation (JAMA): Zafranskaya Marina, Oschmann Patrick, Engel Rosel, et al. Interferon-beta Therapy Reduces Cd4+ and Cd8+ T-cell Reactivity in Multiple Sclerosis.. Immunology May 2007;121:29-39
Abstract
Therapy with interferon-beta (IFN-beta) has well-established clinical effects in multiple sclerosis (MS), albeit the immunomodulatory mechanisms are not fully understood. We assessed the prevalence and functional capacity of CD4+ and CD8+ T cells in healthy donors, and in untreated and IFN-beta-treated MS patients, in response to myelin oligodendrocyte glycoprotein (MOG). The proportion of CD45RO+ memory T cells was higher in MS patients than in healthy donors, but returned to normal values upon therapy with IFN-beta. While CD45RO+ CD4+ T cells from all three groups responded to MOG in vitro, untreated patients showed augmented proliferative responses compared to healthy individuals and IFN-beta treatment reduced this elevated reactivity back to the values observed in healthy donors. Similarly, the response of CD45RO+ CD8+ T cells to MOG was strongest in untreated patients and decreased to normal values upon immunotherapy. Overall, the frequency of peripheral CD45RO+ memory T cells ex vivo correlated with the strength of the cellular in vitro response to MOG in untreated patients but not in healthy donors or IFN-beta-treated patients. Compared with healthy individuals, responding CD4+ and CD8+ cells were skewed towards a type 1 cytokine phenotype in untreated patients, but towards a type 2 phenotype under IFN-beta therapy. Our data suggest that the beneficial effect of IFN-beta in MS might be the result of the suppression or depletion of autoreactive, pro-inflammatory memory T cells in the periphery. Assessment of T-cell subsets and their reactivity to MOG may represent an important diagnostic tool for monitoring successful immunotherapy in MS.
Mesh Headings (Keywords): Adult, Antigens, CD45, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Cell Proliferation, Cells, Cultured, Cytokines, Disease Progression, Flow Cytometry, Humans, Immunologic Memory, Immunophenotyping, Immunosuppressive Agents, Interferon-beta, Lymphocyte Activation, Middle Aged, Multiple Sclerosis, Relapsing-Remitting, Myelin-Associated Glycoprotein, Protein Tyrosine Phosphatase, Non-Receptor Type 1, T-Lymphocyte Subsets
Check for Full Text / PubMed Unique Identifier (PMID): 17239199
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.